Status: Recruiting
FIH Study to Evaluate Safety, Tolerability, PK, PD & Preliminary Efficacy of AT03-65 With Advanced Solid Tumors
A Phase I, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AT03-65 in Adults with Advanced Solid Tumors
Participants needed: 83
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Axcynsis Therapeutics Pte LtdUpdated: Oct 13, 2026Locations: 4
Eligibility criteria
At least 18 years old at the time of signing written informed consent form (ICF)... [+4]
Subjects previously received or is currently receiving any systemic anti-cancer... [+13]